Hair loss protein target revealed? minoxidil study probes JAK2

NCT ID NCT07563036

Recruiting now Knowledge-focused Sponsor: Kasr El Aini Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will measure a protein called JAK2 in the scalps of 25 people with male pattern baldness. Researchers will compare JAK2 levels in balding and non-balding areas, then see if 12 weeks of topical minoxidil 5% changes JAK2 in the balding scalp. The goal is to understand whether JAK2 is involved in hair loss and how minoxidil might work at the tissue level.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Topical minoxidil 5% solution
What this could lead to: If successful, this could reveal whether JAK2 plays a role in hair loss and whether minoxidil works through this pathway, pointing toward new treatment targets.
What could go wrong: This is a very small, early study with only 25 participants and no control group. It measures a protein level, not hair regrowth directly, so results may not lead to a practical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGENETIC ALOPECIA ANDROGENIC ALOPECIA

Contacts and locations

Locations

Kasr El Aini Hospital
RECRUITING

Cairo, Cairo Governorate, 11555, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.